title: Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.
abstract: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83% [95% confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Felipe
authors.initials: F
authors.lastname: Samaniego
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Fredrick
authors.initials: F
authors.lastname: Hagemeister
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Romaguera
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Fanale
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: M Alma
authors.initials: MA
authors.lastname: Rodriguez
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Luis
authors.initials: L
authors.lastname: Fayad
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
authors.affiliation: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Lei
authors.initials: L
authors.lastname: Feng
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Berkova
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Tamer
authors.initials: T
authors.lastname: Khashab
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Lalit
authors.initials: L
authors.lastname: Sehgal
authors.affiliation: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Francisco
authors.initials: F
authors.lastname: Vega-Vasquez
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D015649:Pentostatin / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015649:Pentostatin; D000069283:Rituximab; D003520:Cyclophosphamide
keywords: cyclophosphamide; deoxycoformycin; follicular lymphoma; marginal zone lymphoma; small lymphocytic lymphoma
references.citation: J Clin Oncol. 2006 Apr 1;24(10):1575-81
references.pmid: 16520464
references.citation: J Clin Oncol. 1996 Apr;14(4):1262-8
references.pmid: 8648382
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: J Clin Oncol. 2013 Apr 20;31(12):1506-13
references.pmid: 23530110
references.citation: Eur J Haematol. 2005 Aug;75(2):130-5
references.pmid: 16000129
references.citation: Blood. 2002 Dec 15;100(13):4351-7
references.pmid: 12393618
references.citation: J Clin Oncol. 2004 Jul 1;22(13):2654-61
references.pmid: 15159414
references.citation: Anticancer Drugs. 2002 Oct;13(9):907-13
references.pmid: 12394253
references.citation: Ann Oncol. 2000 Mar;11(3):363-5
references.pmid: 10811507
references.citation: Lancet. 2013 Apr 6;381(9873):1203-10
references.pmid: 23433739
references.citation: J Clin Oncol. 2005 Jun 20;23(18):4079-88
references.pmid: 15767648
references.citation: Leuk Lymphoma. 2014 Apr;55(4):828-33
references.pmid: 23808813
references.citation: Cancer. 2005 Mar 1;103(5):978-84
references.pmid: 15672388
references.citation: Cancer Treat Rev. 2013 Dec;39(8):851-61
references.pmid: 23566572
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1278-84
references.pmid: 12663715
references.citation: Lancet. 2010 Oct 2;376(9747):1164-74
references.pmid: 20888994
references.citation: Blood. 2007 Jan 15;109(2):405-11
references.pmid: 17008537
references.citation: Cancer. 2010 May 1;116(9):2180-7
references.pmid: 20187101
references.citation: Blood. 2013 May 16;121(20):4137-41
references.pmid: 23493782
references.citation: Hematol J. 2000;1(1):53-66
references.pmid: 11920170
references.citation: Blood. 2006 Feb 1;107(3):885-91
references.pmid: 16219797
references.citation: Cancer. 1980 Jan 15;45(2):318-26
references.pmid: 6153152
references.citation: Cancer. 2012 Aug 15;118(16):3954-61
references.pmid: 22179904
references.citation: Blood. 1989 Jul;74(1):19-25
references.pmid: 2473795
references.citation: Blood. 2008 Aug 15;112(4):975-80
references.pmid: 18411418
references.citation: J Clin Oncol. 1989 Oct;7(10):1518-27
references.pmid: 2674337